Abstract
Magnolol has shown inhibitory effects on NO production and TNF-alpha production in lipopolysaccharide (LPS)-activated macrophages and LPS-induced acute lung injury; however, the poor solubility of magnolol has hindered its clinical success. In this study, magnolol-loaded microparticles were prepared via single emulsion method from a polyketal polymer, termed PK3. The particle sizes of magnolol-loaded PK3 microparticle is 3.73 ± 0.41 μm, and was suitable for phagocytosis by macrophages and pulmonary drug delivery. PK3 microparticles exhibited excellent biocompatibility both in vitro and in vivo. More importantly, intratracheal delivery of these magnolol-loaded microparticles significantly reduced the lung inflammatory responses at low dosage of magnolol (0.5 mg/kg), and have great clinical potential in treating acute lung injury.
| Original language | English |
|---|---|
| Pages (from-to) | 401-411 |
| Number of pages | 11 |
| Journal | Journal of Microencapsulation |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Jul 3 2016 |
Keywords
- Magnolol
- acute lung injury
- anti-inflammatory. pulmonary drug delivery
- polyketal microparticles
ASJC Scopus subject areas
- Bioengineering
- Physical and Theoretical Chemistry
- Colloid and Surface Chemistry
- Pharmaceutical Science
- Organic Chemistry